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Background: Cognitive behavioural therapy does not 
reduce fatigue in post-polio syndrome, but is effecti-
ve in facioscapulohumeral dystrophy. This difference 
in efficacy might be explained by a different role of 
cognitions in these conditions.
Objective: To compare fatigue-related cognitions 
between patients with post-polio syndrome and 
facio scapulohumeral dystrophy. 
Subjects: Patients with post-polio syndrome (n = 21) 
and facioscapulohumeral dystrophy (n = 24) alloca-
ted to a cognitive behavioural therapy intervention 
in 2 identical trials.
Methods: Assessed cognitions included: sense of con-
trol over fatigue; catastrophizing; acceptance; focu-
sing on fatigue; and perceived social support. Group 
differences in cognitions (independent t-tests or 
Mann–Whitney U tests) and group differences in the 
association of cognitions with fatigue (linear regres-
sion models) were studied. 
Results: No differences in cognitions were found 
between the 2 groups (p > 0.18). Furthermore, there 
were no cognition-by-group interaction effects, ex-
cept for “perceived social support”, for which a dif-
ferent association with fatigue was found between 
the 2 groups (p = 0.01). However, univariate models 
revealed no associations per group.
Conclusion: Fatigue-related cognitions in severely 
fatigued patients with post-polio syndrome are not 
clearly different from those in facioscapulohumeral 
dystrophy. Thus, the lack of efficacy of cognitive be-
havioural therapy in post-polio syndrome cannot be 
attributed to unique cognitive characteristics of this 
population. 
Key words: cognitive therapy; cognition; facioscapulohu-
meral muscular dystrophy; fatigue; post-poliomyelitis syn-
drome.
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Post-polio syndrome (PPS) is highly prevalent among the ageing population of polio survivors, 
affecting between 15% and 80% of all patients with 
previous paralytic polio (1). Given the large number 
of polio survivors worldwide (2), PPS is currently one 
of the most common motor neurone diseases.
Fatigue is a frequent complaint in people with PPS 
(3–5). In a study on disability and health problems in 76 
Dutch patients with PPS, 78% of the subjects reported 
fatigue as their main problem, exceeding difficulties 
in walking outdoors (45%), climbing stairs (41%) and 
pain (39%) (6). Moreover, compared with healthy in-
dividuals, patients with PPS experienced much higher 
levels of fatigue (7, 8), which was shown to contribute 
considerably to reduced functioning and health-related 
quality of life (HRQoL) (9, 10). 
Fatigue in PPS is considered a multidimensional 
phenomenon. Earlier studies have shown that biologi-
cal, physical and psychological factors are associated 
with this fatigue (11, 12). Given this multidimen-
sional character, a variety of interventions aimed at 
alleviating fatigue have been studied. These include 
both pharmacological and non-pharmacological in-
terventions, such as exercise therapy, (online) fatigue 
management, transcranial direct current stimulation, 
and multidisciplinary rehabilitation. However, due to 
a lack of high-quality randomized controlled trials, no 
definite conclusions on the effectiveness of the above-
mentioned interventions can be made (13). 
We recently reported the results of a randomized 
controlled trial on the efficacy of cognitive behavioural 
therapy (CBT) in severely fatigued patients with PPS. 
In this study, no decrease in fatigue was found (14), de-
spite the effectiveness of this intervention in reducing 
fatigue in various other patient populations (15–17). 
A recent trial investigating the effect of CBT in faci-
oscapulohumeral dystrophy (FSHD), found a clinically 
relevant decline in fatigue after this intervention (18). 
The lack of efficacy of CBT in PPS compared with 
FSHD, change in fatigue score on the subscale fatigue 
severity of the Checklist Individual Strength (CIS): 
+1.87 vs –13.3, respectively, may be linked to the role of 
fatigue-related cognitions. Effective CBT interventions 
for reducing fatigue are based on models of perpetuating 
factors for fatigue, which follow growing evidence that a 
patient’s cognitions and behaviour are related to fatigue 
(19). Also, in diseases characterized by loss of muscle 
function, it has been shown that cognitive-behavioural 
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factors are associated with fatigue (20), which may be 
even more important in the persistence of this symptom 
than the severity of neurological impairment (21). More 
recent studies demonstrated that changes in cognitive 
factors, such as an increase in sense of control over 
fatigue and a reduction in focusing on fatigue symptoms 
(rather than behavioural changes), are mainly associated 
with a reduction in fatigue after CBT (22, 23). 
Most patients with PPS were affected by acute 
polio in their first years of life, and usually grew up 
with residual paresis and deformities. Therefore, these 
patients have spent a lifetime managing the challenges 
of living with functional limitations and generally 
experience long durations of fatigue. As such, it can 
be hypo thesized that they have developed different 
cognitions related to fatigue compared with patient 
populations with a more gradual symptom onset later 
on in their lives, such as in FSHD. 
This study aimed to investigate cognitions related to 
fatigue in severely fatigued patients with PPS compared 
with severely fatigued patients with FSHD. The study 
tested the hypotheses that fatigue-related cognitions 
in PPS are different from those in FSHD, and that the 
association of cognitions with fatigue differs between 
the 2 conditions. Any such difference might explain the 
difference in efficacy of CBT between PPS and FSHD.
METHODS
The data used in this study originate from a multi-centre 3-ar-
med RCT, the Fitness And Cognitive behavioural TherapieS for 
Fatigue and ACTivities in PPS (FACTS-2-PPS) trial, which is 
part of a larger research programme investigating the effects of 2 
rehabilitation interventions in different neuromuscular disorders 
(the FACTS-2-NMD programme). In the PPS trial, the efficacy of 
exercise therapy and of CBT on reducing fatigue and improving 
activities and HRQoL was compared with usual care in patients 
with PPS. The study design, the protocol of both interventions, 
and the main results of the trial are described in previous pu-
blications (14, 24). For the present study, data were used from 
participants who were allocated to the CBT intervention and, as 
part of this intervention, completed computerized questionnaires 
measuring fatigue cognitions. These questionnaires were admi-
nistered to select the appropriate treatment modules in order to 
customize the CBT intervention to the patients’ personal needs. 
The comparison group consisted of patients with FSHD 
who were allocated to the CBT intervention in a second RCT 
conducted within the FACTS-2-NMD programme. This RCT, 
the FACTS-2-FSHD trial (25), was similar to the PPS trial with 
respect to the study objectives, the measurement protocol and the 
protocol of the CBT intervention. Moreover, the interventions 
were carried out in the same centres by the same cognitive beha-
vioural therapists (n = 4), who were highly trained in the protocol. 
Participants 
Participants in the PPS trial and the FSHD trial were recruited 
from 7 hospitals and rehabilitation centres throughout the Nether-
lands. In addition, patients with FSHD who were registered in a 
Dutch neuromuscular database (26) or who participated in a pa-
tient support organization were also invited to participate. Medical 
files were screened for potential eligibility. Patients willing to 
provide signed consent were evaluated by a physician to check 
the inclusion and exclusion criteria. Regarding PPS, the diagnosis 
was based on the criteria of the March of Dimes, which include 
a gradual or sudden onset of progressive and persistent muscle 
weakness, or abnormal muscle fatigability after a period of stable 
neurological function (2). As for FSHD, the diagnosis of FSHD 
type 1 was confirmed by DNA testing. Major inclusion criteria 
in both groups were: severe fatigue (CIS ≥ 35) (27) and walking 
ability with or without a walking aid. Major exclusion criteria 
were: clinical depression and disabling co-morbidity interfering 
with the intervention programme. A complete list of in- and ex-
clusion criteria has been provided elsewhere (24, 25). The study 
protocols of the PPS trial and the FSHD trial were approved by 
the Medical Ethics Committee of the Academic Medical Centre 
in Amsterdam and the Radboud University Medical Center in 
Nijmegen, respectively, and all participating centres granted 
approval to participate. The RCTs were registered in the Dutch 
Trial Register (PPS trial: NTR1371; FSHD trial: NTR1447). 
Written informed consent was obtained from all participants. 
Assessment of fatigue
Fatigue was measured with the subscale fatigue severity of 
the CIS (27), which consists of 8 statements regarding fatigue 
severity as experienced during the previous 2 weeks (I feel 
tired; Physically I feel exhausted; I feel fit; I feel weak; I feel 
rested; Physically I feel I am in a bad condition; I get tired very 
quickly; Physically I feel in a good shape). Participants had to 
indicate on a 7-point Likert scale (ranging from 1 to 7) to what 
extent the particular statement applied to them. The total score 
was calculated as the sum of the responses to the 8 statements. A 
higher fatigue severity score indicates a higher degree of fatigue. 
Fatigue severity scores collected at study entry (pre-treatment 
score) were used in the current study. The CIS fatigue has 
been shown reliable in polio survivors and patients with FSHD 
(Cronbach’s alpha: 0.93 and 0.83–0.92, respectively) (18, 28). 
Assessment of cognitions related to fatigue 
Appendix SI gives an overview of the instruments used for the 
assessment of cognitions related to fatigue, including sense of 
control over fatigue, catastrophizing, acceptance of the disease, 
focusing on fatigue symptoms, and perceived social support. 
Sense of control over fatigue was measured with the Self-Effi-
cacy Scale (SES) (29). Fatigue-related catastrophizing was mea-
sured with the Jacobsen-Fatigue Catastrophizing Scale (J-FCS) 
(30). This scale has been shown to be reliable in patients with 
breast cancer and chronic fatigue syndrome (CFS) (Cronbach’s 
alpha: 0.92 and 0.86, respectively) (30, 31). Pain-related cata-
strophizing was measured with the Pain Catastrophizing Scale 
(PCS) (32). The impact of being diagnosed with and treated for 
the disease was measured with the Impact of Event Scale (IES) 
(33). This instrument has been shown to be reliable and valid 
in different samples confronted with various kinds of traumatic 
incidents (33). Acceptance of the disease was measured with the 
corresponding subscale of the Illness Cognitions Questionnaire 
(ICQ acceptance) (34). This subscale is reliable and has been 
shown to be valid in patients with rheumatoid arthritis and 
multiple sclerosis (Cronbach’s alpha: 0.90 and 0.91; Pearson’s 
1http://www.medicaljournals.se/jrm/content/?doi=10.2340/16501977-2247
www.medicaljournals.se/jrm
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correlation coefficient: 0.76 and 0.78) (34). Focusing on fatigue 
symptoms was assessed with the corresponding subscale of the 
Illness Management Questionnaire (IMQ focusing on symptoms) 
(35). The IMQ was developed and validated in CFS and showed 
good internal consistency (Cronbach’s alpha: 0.88) (35). Discre-
pancies between the received amount of social support and the 
desired amount of social support were assessed with the Social 
Support Inventory (SSI discrepancies) (36). 
Statistical analysis
Sociodemographic characteristics, disease characteristics and 
cognitions of both groups are presented as means (SD) or medians 
(range) for numerical variables, and as number (%) for categorical 
variables. Group differences in fatigue-related cognitions were 
studied using independent t-tests (continuous variables with nor-
mal distribution) or Mann–Whitney U tests (continuous variables 
with non-normal distribution). Associations between cognitions 
and fatigue were investigated with linear regression analyses. 
First, univariate associations between cognitions and fatigue were 
explored for the combined groups. Next, to evaluate group diffe-
rences in the associations of cognitions with fatigue, multivariable 
linear regression models were built including cognition, group and 
the interaction term of cognition-by-group. In case of a significant 
cognition-by-group interaction effect, the univariate association 
between the respective cognition and fatigue for each group was 
investigated. Model assumptions (normality, linearity, homo-
geneity and independence of random errors) were checked using 
residual plots. All analyses were performed with SPSS Statistics 
21. An alpha level of 0.05 was used for all tests of significance.
RESULTS
In the PPS trial, 23 participants were allocated to CBT. 
The intervention was not initiated with 5 participants 
because they did not prioritize fatigue as a treatment 
goal. Of these 5, for the same reason 2 also did not 
complete the computerized questionnaires. Therefore, 
data from 21 participants with PPS were available. Of 
the 25 participants allocated to CBT in the FSHD trial, 
the results for 1 participant were not available due to a 
technical problem with the computerized questionnaires. 
Therefore, data from 24 partici-
pants with FSHD were available.
Sociodemographic and di-
sease characteristics of both 
groups are shown in Table I. The 
patients with PPS differed from 
those with FSHD in that they 
were older (mean difference: 8.7 
years (95% confidence interval 
(95% CI) 1.8–15.6 years)), had 
a longer illness duration, defined 
as time since diagnosis of acute 
polio/FSHD (mean difference: 
42.9 years (95% CI 36.4–49.4 
years)), and had a longer dura-
tion of fatigue symptoms (mean 
difference: 5.2 years (95% CI 
0.8–9.7 years)). No significant differences were found 
between the groups with respect to sex, ethnicity, social 
status, education, employment, and fatigue severity, as 
measured with the CIS. Also, the number of treatment 
sessions that participants received did not differ bet-
ween the groups (median number of treatment sessions 
8 (range 1–12) and 5 (range 1–13) for PPS and FSHD, 
respectively, p = 0.24). 
Cognitions related to fatigue in PPS compared with 
FSHD are shown in Table II. No significant differences 
Table I. Sociodemographic and disease characteristics of 
patients with post-polio syndrome (PPS) and those with 
facioscapulohumeral dystrophy (FSHD) 
PPS (n = 21) FSHD (n = 24)
Sociodemographic characteristics
Female, n (%) 12 (57) 7 (29)
Age, years, mean (SD) [range] 60.0 (8.6)  
[38–72]
51.3 (13.4) 
[24–76]
Caucasian ethnicity, n (%) 20 (95) 24 (100)
Married or partner, n (%) 15 (71) 18 (75)
College or university degree, n (%) 10 (48) 8 (33)
> 20 h/week paid work, n (%) 4 (19) 11 (46)
Disease characteristics
Time since diagnosis acute polio/FSHD, 
years, mean (SD)
57.3 (8.1) 14.4 (13.0)
Time since fatigue symptoms, years, 
mean (SD)
12.5 (6.7) 7.2 (7.4)
Fatigue severity (CIS), mean (SD)a 40.0 (8.8) 43.1 (5.8)
MMT sum score legs, median (range)b 70.3 (45.5–79.3)
MMT sum score arms, median (range)c 50 (37.8–50.0)
Present walking distance, n (%)d
Around the house 7 (33)
Seldom further than 1 km 11 (52)
Regularly further than 1 km 3 (14)
Ricci score, mean (SD)e 2.7 (1.0)
aCIS: subscale fatigue severity of the Checklist Individual Strength (range 8–56, 
higher scores indicating more fatigue). bSum score for muscle strength of the 
legs was calculated by adding the scores of 16 muscle groups. Each muscle 
group had a score between 0 and 5; sum score ranged from 0 to 80. cSum 
score for muscle strength of the arms was calculated by adding the scores 
of 10 muscle groups. Each muscle group had a score between 0 and 5; sum 
score ranged from 0 to 50. dWalking distance was classified into 3 categories: 
around the house; seldom further than 1 km; regularly further than 1 km. 
eRicci score: disease severity of FSHD (range 0–15, higher scores representing 
more impairment). MMT: manual muscle testing; SD: standard deviation.
Table II. Fatigue-related cognitions in post-polio syndrome (PPS) compared with 
facioscapulohumeral dystrophy (FSHD)
PPS (n = 21) FSHD (n = 24)
p-value
Mean 
difference 95% CIn Mean (SD) n Mean (SD)
Sense of control over fatigue
SES 20 19.7 (3.4) 23 20.4 (3.1) 0.49 –0.7 –2.7 to 1.3
Catastrophizing
J–FCS 20 2.0 (0.7) 23 1.7 (0.6) 0.19 0.3 –0.1 to 0.7
*PCS 20 4.5 (0 to 13) 20 3.0 (0 to 10) 0.28 – –
*IES 20 9.0 (0 to 46) 23 6.0 (0 to 37) 0.18 – –
Acceptance of the disease
ICQ acceptance 20 17.0 (3.9) 24 17.4 (5.5) 0.80 –0.4 –3.3 to 2.6
Focusing on fatigue symptoms 
IMQ focusing on fatigue symptoms 20 2.8 (1.2) 24 3.1 (1.1) 0.32 –0.3 –1.0 to 0.3
Perceived social support 
SSI discrepancies 20 10.2 (1.7) 24 9.8 (2.6) 0.51 –0.9 to 1.8
*Median (range). CI: confidence interval; FSHD: facioscapulohumeral dystrophy; ICQ: Illness Cognitions 
Questionnaire; IES: Impact of Event Scale; IMQ: Illness Management Questionnaire; J-FCS: Jacobsen-fatigue 
catastrophizing scale; PCS: Pain Catastrophizing Scale; SD: standard deviation; SES: Self-Efficacy Scale; 
SSI: Social Support Inventory.
J Rehabil Med 49, 2017
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in the level of any of the cognitive factors were found 
between the groups. The results of the univariate and 
multivariate linear models for the whole group are 
shown in Table III. None of the models showed a sig-
nificant cognition-by-group interaction effect, except 
for the model testing the association of perceived 
social support and fatigue (β “SSI discrepancies-by-
group” = –2.65, SE 1.03, p = 0.01). Univariate models 
of this association for each group separately showed 
that there was no significant association (β = 2.03, SE 
1.01, p = 0.06 and β = –0.62, SE 0.46, p = 0.19 for PPS 
and FSHD, respectively). 
DISCUSSION 
Fatigue-related cognitions in severely fatigued patients 
with PPS were not found to be significantly different 
from those of severely fatigued patients with FSHD at 
the time of inclusion in an RCT aimed at alleviating 
fatigue. Also, no differences in the association of the 
assessed cognitions with fatigue were found between 
the 2 groups, except for the cognition perceived so-
cial support. As such, the results of this study do not 
support the hypothesis that patients with PPS develop 
different cognitions related to fatigue during their lives 
compared with a patient population with a more gra-
dual symptom onset later in their lives, namely FSHD. 
Fatigue-related cognitions in patients with PPS in 
our study were shown to be similar to those in patients 
with FSHD, but also to those in other patient popu-
lations with a shorter duration of disease symptoms. 
For example, the mean scores on the factors “fatigue-
related catastrophizing” and “focusing on fatigue 
symptoms” were similar to those in patients with CFS 
(31, 35). For the factor “acceptance of the disease”, 
our patients scored in the same range as patients with 
multiple sclerosis or rheumatoid arthritis (34). Our 
patients also scored similar levels of distress resulting 
from traumatic stressors (i.e. the traumatic life event 
of being diagnosed with or treated for polio and PPS) 
compared with patients with work-related trauma (33). 
As such, it is suggested that the role of fatigue-related 
cognitions in PPS does not explain the lack of efficacy 
of CBT in this patient group as observed in the FACTS-
2-PPS trial. This suggestion is also corroborated by 
the fact that no differences in the association of the 
assessed fatigue-related cognitions with fatigue were 
found between the 2 groups, except for the cognition 
perceived social support. However, the low absolute 
scores on this factor in both groups, and the lack of an 
association with fatigue per group, indicate that per-
ceived social support is not a major problem in these 
2 groups. It therefore seems unlikely that this single 
finding could have explained the observed difference 
in efficacy of CBT in PPS and FSHD. 
Thus, the question remains as to why a cognitive 
behavioural approach aimed at reducing fatigue in 
PPS was not effective. It may be that cognitive pat-
terns in people affected with PPS are more difficult to 
change due to their specific disease history usually with 
functional limitations from an early age and, added 
thereto, the long-term duration of fatigue, as found in 
this study. However, there is currently no evidence in 
the literature to support this hypothesis and, as no post-
treatment data on the cognitive factors were collected 
in this study, we were not able to test this hypothesis. 
Table III. Univariate and multivariate regression models for 
fatigue severity (CIS) for the total group post-polio syndrome 
(PPS) and facioscapulohumeral dystrophy (FSHD)
β SE p-value
SES Univariate model (n = 43)
SES –0.91 0.31 0.01
Multivariate model (n = 43)
SES –1.41 0.42 0.00
Diagnosis –14.84 12.34 0.24
SES*Diagnosis 0.90 0.61 0.15
J-FCS Univariate model (n = 43)
J-FCS 3.59 1.54 0.03
Multivariate model (n = 43)
J-FCS 3.04 2.10 0.15
Diagnosis –0.98 6.11 0.87
J-FCS *Diagnosis 2.51 3.10 0.42
PCS Univariate model (n = 40)
PCS 0.07 0.30 0.83
Multivariate model (n = 40)
PCS 0.06 0.40 0.89
Diagnosis 1.31 3.59 0.72
PCS *Diagnosis 0.18 0.65 0.78
IES Univariate model (n = 43)
IES 0.50 0.09 0.55
Multivariate model (n = 43)
IES 0.06 0.11 0.59
Diagnosis 2.60 3.03 0.40
IES *Diagnosis 0.02 0.17 0.89
ICQ 
acceptance
Univariate model (n = 44)
ICQ acceptance –0.55 0.21 0.01
Multivariate model (n = 44)
ICQ acceptance –0.77 0.39 0.05
Diagnosis –2.50 8.12 0.76
ICQ acceptance *Diagnosis 0.29 0.46 0.53
IMQ focusing 
on fatigue 
symptoms
Univariate model (n = 44)
IMQ focusing on fatigue symptoms 3.19 0.83 0.00
Multivariate model (n = 44)
IMQ focusing on fatigue symptoms 4.05 1.22 0.00
Diagnosis 6.66 5.36 0.22
IMQ focusing on fatigue symptoms 
*Diagnosis
–1.81 1.69 0.29
SSI 
discrepancies
Univariate model (n = 44)
SSI discrepancies 0.05 0.49 0.92
Multivariate model (n = 44)
SSI discrepancies 2.03 0.88 0.03
Diagnosis 29.06 10.56 0.01
SSI discrepancies *Diagnosis –2.65 1.03 0.01
Diagnosis: PPS: 0; FSHD: 1
CIS: Checklist Individual Strength; ICQ: Illness Cognitions Questionnaire; 
IES: Impact of Event Scale; IMQ: Illness Management Questionnaire; J-FCS: 
Jacobsen-fatigue catastrophizing scale; PCS: Pain Catastrophizing Scale; 
SE: standard error; SES: Self-Efficacy Scale; SSI: Social Support Inventory.
www.medicaljournals.se/jrm
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of severely fatigued patients with FSHD and probably 
also to other populations with a symptom onset later 
on in their lives who have been proven to benefit from 
CBT interventions aimed at reducing fatigue (31, 34, 
35). Thus, the observed lack of efficacy of CBT in the 
FACTS-2-PPS trial cannot be attributed to unique cogni-
tive characteristics of patients with PPS. Further studies 
should investigate the perceived distress from fatigue, 
acceptance of fatigue symptoms and the felt need for 
treatment in alleviating fatigue in PPS and, specifically, 
whether a low need for treatment of fatigue explains, at 
least in part, the lack of efficacy of a cognitive behaviou-
ral approach to reduce fatigue in this population. If this 
latter can be confirmed, better selection of PPS patients 
with a high priority for alleviating fatigue may result in 
more effective application of CBT in this population. 
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